Isodiol International Inc.

OTC: ISOLF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Vancouver, BCReports USD

#569 of 1,394 Healthcare companies by revenue58th-percentile growth

EA Score

——

FH —DQ —GM —SS 31

v0.1 · 5/100 weight · pillars only

↑ 3-yr revenue growth, Piotroski F · ↓ Altman-Z, return on equity

Methodology →

Revenue TTM

$11.9k

Rev growth YoY (TTM)

-17.7%

Net income (FY)

-$90.3M

Employees

—

Market cap

$4.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$16.7M$16.7M2018

Net income-$90.3M-$90.3M2018

Operating income-$29.2M-$29.2M2018

Total assets$17.7M$17.7M2018

Liabilities$12.5M$12.5M2018

Equity$5.2M$5.2M2018

Revenue trend

FY2015 – FY2018 · USD

$13.0k

FY15

$266.9k

FY16

$14.8M

FY17

$16.7M

FY18

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Isodiol International Inc. booked $16.7M in FY2018 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a -542.1% net margin.

Peers · Healthcare

Arno Therapeutics, Inc.——Rising Biosciences, Inc.——Sentry Petroleum Ltd——Flower One Holdings Inc.——

Key facts

CEOMarcos Agramont

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersVancouver, BC

ExchangeOTC: ISOLF

Employees—

IPO date2014-11-20

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.